


Mutational Signature


Percent of SNVs
attributed to signature




Treatment

carboplatin
paclitaxel
iposomal doxorubicin
gemcitabine
cyclophosphamide
topotecan
cisplatin
olaparib
bevacizumab
docetaxel
farletuzumab/placebo
nab-paclitaxel
etoposide

Cisplatin *G. gallus*
Cyclophosphamide *G. gallus*
Etoposide *G. gallus*
Cisplatin *C. elegans*
(1) Age
(2) BRCA
(3) MMR
(4) AID
(5) POLE
(6) AID
(7) AID
(8) AID
(9) AID
(10) POLE
(11) AID
(12) AID
(13) AID
(14) AID
(15) AID
(16) AID
(17) AID
(18) AID
(19) AID
(20) AID
(21) AID
(22) AID
(23) AID
(24) AID
(25) MMR
(26) MMR
(27) MMR
(28) MMR
(29) Tobacco
(30) Tobacco



Pre-treatment



Post-treatment unique